Pomalidomide

Pomalidomide is an immunomodulatory antineoplastic agent. The chemical name is (RS)-4-Amino-2-(2,6-dioxo-piperidin-3-yl)-isoindoline-1,3-dione. It is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Isoindoles and Derivatives. . The Molecular Weight of Pomalidomide is 273.24.
Contraindications
Pomalidomide
Effects
The symptomatic adverse reactions produced by Pomalidomide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Fatigue, Nausea, Diarrhea, Constipation, Confusion, Asthenia, Neutropenia, Pyrexia, Anemia, Back pain, Confusion, dizziness, tumor lysis syndrome, upper GIT infecyion.
Indications
Pomalidomide is primarily indicated in conditions like Multiple myeloma.
Interactions
No data regarding the interactions of Pomalidomide was found.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Capsule Store Between 20°C-25°C.
Warnings
Embryo Fetal toxicity,Patint must not donate blood during treatment with pomalidomide,Hematologic Toxicity,Tumor Lysis Syndrome (TLS),Thromboembolic events,Peripheral neuropathy,Significant cardiac dysfunction,Second Primary Malignancies, dizziness and confusion in all the above mentioned conditions, appropriate caution should be exercised when considering the treatment of such patients with pomalidomide.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.